Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company founded in 1987. The company is focused on developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease, and type 2 diabetes within the Biotechnology and Health Care industries.
As of the latest available information, there is no record of the last investment or the investors involved in the most recent funding round for Capstone Therapeutics.
In summary, Capstone Therapeutics, established in 1987, is a clinical stage biotechnology company specializing in the development of peptide drugs for cardiovascular patients. The company's lead molecule, AEM-28, has received FDA Orphan drug designation for HoFH and targets multiple indications within the cardiovascular and metabolic disease areas. While the latest investment details are not available, Capstone's focus on addressing unmet medical needs in high cholesterol and triglyceride levels presents potential opportunities for investors in the biotechnology and healthcare sectors.
